Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive


Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

GSK Teams with Shenzhen Neptunus for Chinese Vaccines

June 10, 2009

GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people.

GSK Signs Deal with Concert Pharma to the Tune of $1 Billion

June 3, 2009

GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body.

Pfizer and Glaxo Join Forces in HIV Venture

April 22, 2009

The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.

GSK Grabs Derma Firm for $2.9 Billion

April 22, 2009

Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.

A Season in Financial Hell

April 1, 2009

From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal.

Gilead Buys CV Therapeutics (Update 1)

March 12, 2009

The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.

Roche and Genentech Seal the Deal for $46.8 Billion

March 5, 2009

After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.

Merck Takes Unusual Merger Tactic in Schering Deal

March 4, 2009

The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?

Astellas to Nominate Two Directors to CV Therapeutics Board

March 3, 2009

Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own.


Click here